^
    Back
    Association details:
    Biomarker:BCR-ABL1 L248V
    Cancer:Chronic Myeloid Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) +
    imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) +
    Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Blood
    Title:

    Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

    Excerpt:
    Spectrum and frequency of BCR-ABL kinase domain mutations recovered in the presence of imatinib mesylate, nilotinib, and dasatinib...In a pilot experiment, mutagenized Ba/F3-p210BCR-ABL cells were exposed to pairwise combinations of imatinib mesylate, nilotinib, and dasatinib (Table S2). In all cases, a more profound suppression of growth was observed with the combinations as compared with single agents.
    DOI:
    10.1182/blood-2006-02-004580